GB201019525D0 - Oil-based formulations - Google Patents

Oil-based formulations

Info

Publication number
GB201019525D0
GB201019525D0 GB201019525A GB201019525A GB201019525D0 GB 201019525 D0 GB201019525 D0 GB 201019525D0 GB 201019525 A GB201019525 A GB 201019525A GB 201019525 A GB201019525 A GB 201019525A GB 201019525 D0 GB201019525 D0 GB 201019525D0
Authority
GB
United Kingdom
Prior art keywords
prodrug
gut lumen
oil
premature
premature hydrolysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201019525A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Shire LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire LLC filed Critical Shire LLC
Priority to GB201019525A priority Critical patent/GB201019525D0/en
Publication of GB201019525D0 publication Critical patent/GB201019525D0/en
Priority to PCT/GB2011/052262 priority patent/WO2012066347A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the use of oil based delivery vehicles to prevent undesirable premature hydrolysis of phenolic amino benzoic acid carbamate prodrugs, while resident in the gut lumen. Preclusion of water and hydrolytic enzymes prior to prodrug absorption ensures that such compounds can be fully absorbed intact without undergoing unintended premature hydrolysis in the gastrointestinal tract so maximizing the benefit of improved systemic availability afforded by the prodrug. Furthermore judicious selection of oil and prodrug salt form can result in a sustained release plasma PK profile. The avoidance of premature degradation and release of active drug into the gut lumen minimizes any potential for a direct adverse interaction within the gut lumen.
GB201019525A 2010-11-18 2010-11-18 Oil-based formulations Ceased GB201019525D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201019525A GB201019525D0 (en) 2010-11-18 2010-11-18 Oil-based formulations
PCT/GB2011/052262 WO2012066347A1 (en) 2010-11-18 2011-11-18 Oil based formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201019525A GB201019525D0 (en) 2010-11-18 2010-11-18 Oil-based formulations

Publications (1)

Publication Number Publication Date
GB201019525D0 true GB201019525D0 (en) 2010-12-29

Family

ID=43431636

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201019525A Ceased GB201019525D0 (en) 2010-11-18 2010-11-18 Oil-based formulations

Country Status (2)

Country Link
GB (1) GB201019525D0 (en)
WO (1) WO2012066347A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019007441A1 (en) * 2017-07-04 2019-01-10 山东丹红制药有限公司 Sustained release suspension containing dezocine analogue ester and preparation method therefor
EP3946547A4 (en) * 2019-03-26 2023-01-18 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628796B2 (en) * 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
RU2012106605A (en) * 2009-07-23 2013-08-27 ШАЙЕ ЭлЭлСи AMINO ACID AND PEPTIDE MEDICINES OF HALANTAMINE AND THEIR APPLICATION
WO2011133151A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof

Also Published As

Publication number Publication date
WO2012066347A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
IL259334A (en) Biodegradable lipids for the delivery of active agents
IL208260A0 (en) Nanoparticles for targeted delivery of active agents to the lung
WO2011163594A3 (en) Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
WO2011012816A3 (en) Pharmaceutical formulation
IL222548A (en) Hydroxamic acid derivatives and pharmaceutical compositions and antimicrobial agents comprising the same
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
EP2419138A4 (en) Gel compositions for administration of pharmaceutically active compounds
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
EP3677261B8 (en) Administration of serine protease inhibitors to the stomach
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012040331A3 (en) Multistage nanoparticles
IL205313A0 (en) Pharmaceutical formulation of clavulanic acid
WO2011129579A3 (en) Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
WO2012064302A3 (en) Improved montelukast formulations
GB201019525D0 (en) Oil-based formulations
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2013068960A3 (en) Monounsaturated fatty acid for nailcare
MX346316B (en) Pharmaceutical or neutraceutical formulation.
PL2585041T3 (en) Taste-masked pharmaceutical formulation having accelerated onset of action
MX2015006011A (en) Medicinal lozenge based on ibuprofen sodium dihydrate.
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
EP2175862A4 (en) Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
WO2012064306A3 (en) Effervescent formulations of rosuvastatin
WO2011152805A3 (en) Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)